<DOC>
	<DOC>NCT02608697</DOC>
	<brief_summary>The purpose of this placebo-controlled, double-blind study is to assess the effect of several doses of CAT-2054 on LDL-C in hypercholesterolemic patients on a stable dose of high-intensity statin, and to evaluate the safety and tolerability of different doses of CAT-2054 for 4 weeks.</brief_summary>
	<brief_title>A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Between 18 and 74 years at Screening Hypercholesterolemia (LDLC ≥ 70 mg/dL and &lt; 190 mg/dL) plus a stable dose of statin for at least 4 weeks prior to Screening Satisfies one of the following: 1. Female patients of childbearing potential must have used appropriate and highly effective contraception (a regimen which results in a failure rate of &lt;1% per year) with their partners for 4 weeks prior to Screening, and remain compliant during the treatment phase and until 4 weeks after the last dose of investigational product 2. Male patients must use an acceptable and highly effective contraceptive method during the treatment phase and until 4 weeks after the last dose of investigational product Body mass index (BMI) ≤45 kg/m2 History of any major cardiovascular event (stroke, TIA, MI, PTCI, CABG, hospitalization due to heart failure) within 6 months of Screening Type I diabetes mellitus or use of insulin Active peptic ulcer disease or a history of muscle disease or myopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>